During the closeout visit, a monitor is completing the documentation of reconciliation of investigational product. All packaging, as well as the used…

The research site's responsibility for the investigational product (IP) concludes when the product is returned to the sponsor. In this scenario, all IP is being returned to the sponsor for final disposition. The sponsor, not the site, will then manage the destruction process and obtain the corresponding certificate. The site's essential records must document the complete lifecycle of the IP while under its control, from receipt to its return to the sponsor. Therefore, the certificate of destruction, which is generated after the IP has left the site's custody, is not a required site document.

A. Records of investigational product shipment: These are required to document both the initial receipt of the IP from the sponsor and its final return, proving the chain of custody.

B. Investigational product accountability forms: These forms are crucial for tracking the dispensing, administration, and return of the IP for each subject, forming the core of IP reconciliation.

C. Investigational product inventory forms: These are necessary to maintain a running inventory of all IP received, used, and remaining at the site, ensuring full accountability.

1. International Council for Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2):

Section 4.6.3: States the investigator "should maintain records of the product’s delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product." This supports the requirement for options A, B, and C.

Section 5.14.3: Specifies that the sponsor's procedures should address the "return of unused investigational product(s) to the sponsor (or alternative disposition if authorized by the sponsor...)." This delineates the site's responsibility as returning the product, while final disposition (including destruction) is the sponsor's responsibility.

2. U.S. Food and Drug Administration (FDA) Code of Federal Regulations:

21 CFR 312.62(a): "An investigator is required to maintain adequate records of the disposition of the drug... If the investigation is... completed, the investigator shall return the unused supplies of the drug to the sponsor, or otherwise provide for disposition of the unused supplies of the drug as directed by the sponsor." This confirms the site's obligation is to return the IP, with the subsequent destruction and its documentation (the certificate) falling under the sponsor's purview.

3. Johns Hopkins University, Institute for Clinical and Translational Research: Guideline on Investigational Product Accountability.

Section: Study Close-out: "At the end of the study, all unused study drug must be returned to the sponsor or destroyed locally per the sponsor’s instructions. Documentation of the final disposition of the study drug must be maintained in the study files." In this question's scenario, the instruction is to return the IP, so the site's documentation would be the shipping records of the return, not a certificate of destruction.